Arcus Biosciences, Inc.
About Arcus Biosciences, Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $33.0M
- Net income
- -$353.0M
- Total assets
- $1.1B
- Market cap
- $2.9B
- Operating margin
- -156.3%
- Net margin
- -142.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $247.0M
- Operating expenses
- $633.0M
- Operating income
- -$386.0M
- Income tax
- $0
- Net income
- -$353.0M
- EPS (basic)
- $-3.29
- EPS (diluted)
- $-3.29
Balance sheet
- Total assets
- $1.1B
- Current assets
- $1.0B
- Total liabilities
- $508.0M
- Current liabilities
- $231.0M
- Shareholders’ equity
- $631.0M
Cash flow
- Operating cash flow
- -$482.0M
- Investing cash flow
- $66.0M
- Financing cash flow
- $488.0M
- Net cash flow
- $72.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.9B
- EPS (diluted)
- $-3.29
- Shares outstanding
- 125.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 15, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $353.0M in FY2025.
- Revenue declined 35% from FY2021 to FY2025.
- Trading 12% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Arcus Biosciences, Inc..
Write a review
News about Arcus Biosciences, Inc.
News & sentiment via Polygon.io
